ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation

BACKGROUND: Activation of bypass signaling pathways, impairment of apoptosis and mutation of epidermal growth factor receptor (EGFR) to a drug-resistant state are well known mechanisms of resistance to single-agent erlotinib therapy in non-small-cell lung cancer (NSCLC) driven by EGFR mutations. Orp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Transl Lung Cancer Res
Autori principali: Karachaliou, Niki, Gimenez-Capitan, Ana, Drozdowskyj, Ana, Viteri, Santiago, Moran, Teresa, Carcereny, Enric, Massuti, Bartomeu, Vergnenegre, Alain, de Marinis, Filippo, Molina, Miguel Angel, Teixido, Cristina, Rosell, Rafael
Natura: Artigo
Lingua:Inglês
Pubblicazione: Pioneer Bioscience Publishing Company 2014
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367691/
https://ncbi.nlm.nih.gov/pubmed/25806291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.03.02
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi